Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GDTC
#4971
CytoMed Therapeutics Limited Ordinary Shares
1.0
8
+5.88%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+5.88%
Monthly Change
+35.00%
6 month change
-46.27%
Year Change
-59.85%
Previous Close
1.0
2
Open
1.0
8
Bid
Ask
Low
1.0
8
High
1.0
8
Volume
1
Markets
US Stock Market
Healthcare
GDTC
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
11.53 M
11.54 M
11.54 M
—
Valuation ratios
Enterprise value
—
46.17 M
35.85 M
—
Price to earnings ratio
—
—
—
—
Price to sales ratio
—
—
—
—
Price to cash flow ratio
—
—
—
—
Price to book ratio
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.6
-0.33
-0.25
—
Return on equity %
-5.34
-0.37
-0.28
—
Return on invested capital %
—
—
—
—
Gross margin %
—
—
100
—
Operating margin %
—
—
-907.91
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
-3 628.51
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
0.6
14.08
9.89
—
Inventory turnover
—
—
—
—
Asset turnover
0
0
0.01
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
—
—
—
—
Net current asset value per share
—
—
—
—
Tangible book value per share
—
—
—
—
Working capital per share
—
—
—
—
Book value per share
—
—
—
—
News
CytoMed stock jumps after announcing clinical trial partnership in Malaysia
CytoMed Therapeutics enters clinical trial agreement with Malaysian hospital
CytoMed Therapeutics secures $500,000 investment for subsidiary
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
CytoMed reports promising preclinical results for leukemia treatment
CytoMed Therapeutics shareholders approve all proposals at annual meeting
CytoMed Therapeutics schedules annual shareholder meeting